Multiple myeloma is a blood cancer involving abnormal plasma cells in the bone marrow. Treatment can vary considerably depending on disease characteristics, previous treatment, overall health, kidney function, age, and whether the disease has returned. This guide explains common multiple myeloma treatment options, medication groups, stem cell transplantation, newer immune based approaches, and supportive care. The information is intended for general education and can help readers understand common treatment discussions with a qualified healthcare professional.
Multiple myeloma develops when abnormal plasma cells accumulate in the bone marrow and can affect bones, blood counts, kidneys, and other parts of the body. Treatment is individualized rather than based on a single standard medication. Doctors consider factors such as whether the disease is newly diagnosed or relapsed, overall health, previous therapies, and eligibility for stem cell transplantation.
How Multiple Myeloma Treatment Is Chosen
Treatment planning generally begins with an assessment of the person's disease and overall health. Some people may receive several medicines together because different treatments can target myeloma cells in different ways.
Common considerations include:
- Whether the disease is newly diagnosed or has returned
- Previous medications and response to treatment
- Eligibility for an autologous stem cell transplant
- Kidney function and other health conditions
- Risk features of the myeloma
- Potential treatment side effects
- Overall goals of care
For some newly diagnosed patients, combinations involving a proteasome inhibitor, an immunomodulatory medicine, a corticosteroid, and an antibody may be considered. Daratumumab combined with bortezomib, lenalidomide, and dexamethasone is one example of a regimen used in appropriate patients. FDA approvals have expanded the use of such combinations for different patient groups.
Guide to Common Multiple Myeloma Medicines
Multiple myeloma medicines belong to several different groups. The exact combination and treatment schedule depend on the individual situation.
| Medication group | Examples | General role |
|---|---|---|
| Proteasome inhibitors | Bortezomib, carfilzomib, ixazomib | Help interfere with protein processing in myeloma cells |
| Immunomodulatory medicines | Lenalidomide, pomalidomide, thalidomide | Affect myeloma cells and immune activity |
| Monoclonal antibodies | Daratumumab, isatuximab, elotuzumab | Target specific proteins associated with myeloma cells |
| Corticosteroids | Dexamethasone | Commonly combined with other medicines |
| Alkylating medicines | Melphalan, cyclophosphamide | Damage cancer cell DNA |
| Nuclear export inhibitor | Selinexor | Interferes with cellular protein transport |
| Bispecific antibodies | Teclistamab, elranatamab, talquetamab | Help direct immune cells toward myeloma cells |
| CAR T cell therapies | Idecabtagene vicleucel, ciltacabtagene autoleucel | Use modified immune cells to recognize myeloma |
The National Cancer Institute lists these and other medicines among FDA-approved drugs or commonly used treatments for multiple myeloma and related plasma cell disorders.
How Stem Cell Transplant May Fit Into Treatment
An autologous stem cell transplant may be considered for some people who are medically able to undergo the procedure. Typically, the patient's own blood-forming stem cells are collected before intensive treatment and later returned to the body.
Stem cell transplantation is not appropriate for everyone. Age, general health, organ function, previous treatment, and the expected risks of transplantation can influence the decision.
People who are not eligible for transplant can also have several medication-based treatment approaches. In January 2026, the FDA approved daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for certain adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Find Options for Relapsed or Refractory Myeloma
Multiple myeloma can sometimes return after an initial response, which is known as relapsed disease. In other situations, the cancer may not respond adequately to treatment, described as refractory disease.
Treatment choices at this stage depend heavily on which medicines have already been used and whether the disease is resistant to particular drug classes.
Options can include:
- Different combinations of proteasome inhibitors and immunomodulatory medicines
- Monoclonal antibody based combinations
- Bispecific antibody therapies
- CAR T cell therapy
- Other targeted medicines
- Clinical trials
Newer immune based treatments have expanded the options for people with relapsed or refractory disease. For example, FDA approvals in 2026 expanded the use of teclistamab, including its combination with daratumumab for certain patients after previous therapy.
CAR T cell therapies such as idecabtagene vicleucel and ciltacabtagene autoleucel are also included among FDA-approved multiple myeloma treatments for appropriate patients after previous lines of therapy.
Why Supportive Care Matters
Multiple myeloma and its treatments can affect bones, blood counts, kidneys, nerves, and infection risk. Supportive care may therefore be an important part of an overall treatment plan.
Depending on individual needs, healthcare professionals may consider:
- Medicines that help protect bone health
- Treatment for anemia or other blood count problems
- Infection prevention and monitoring
- Management of treatment-related nerve symptoms
- Kidney protection and monitoring
- Pain management
- Regular blood and imaging tests
Supportive treatments are not necessarily directed at killing myeloma cells. Instead, they can help manage complications and improve day-to-day care.
Tips for Understanding a Treatment Plan
Because multiple myeloma treatment can involve several medicines, it can help to keep an updated medication list and understand why each medicine is being used.
Useful questions to discuss with a healthcare professional include:
- What type and risk category of myeloma is present?
- What is the purpose of each medicine?
- How long is each treatment expected to continue?
- What side effects should be reported promptly?
- Is stem cell transplantation appropriate?
- What monitoring tests will be needed?
- What options may be considered if the disease returns?
- Are clinical trials appropriate?
Medication names, approved uses, and treatment recommendations can change as new evidence becomes available. The FDA and NCI maintain current information on approved multiple myeloma medicines and treatment developments.
Conclusion
Multiple myeloma treatment has developed into a broad range of approaches that can include combination medicines, monoclonal antibodies, stem cell transplantation, targeted treatments, bispecific antibodies, and CAR T cell therapies. The appropriate approach depends on the person's disease characteristics, previous treatment, health status, and treatment goals. New approvals continue to expand the available options, making individualized discussion with a qualified hematologist or oncologist especially important. This article is for general education only and is not a substitute for personalized medical advice.